Suppr超能文献

浅度烧伤的治疗:一项使用Transcyte的前瞻性随机试验。

Treatment of partial-thickness burns: a prospective, randomized trial using Transcyte.

作者信息

Kumar Rohit J, Kimble Roy M, Boots Robert, Pegg Stuart P

机构信息

Stuart Pegg Burns Unit, Royal Children's Hospital, Brisbane, Queensland, Australia.

出版信息

ANZ J Surg. 2004 Aug;74(8):622-6. doi: 10.1111/j.1445-1433.2004.03106.x.

Abstract

BACKGROUND

The purpose of the present study was to compare the effectiveness of three burns dressings (TransCyte, a bio-engineered skin substitute; Biobrane; and Silvazine cream (silver sulphadiazine and 0.2% chlorhexidine)), in treating children with partial-thickness burns. The primary objective was to determine the days until > or =90% re-epithelialization. The secondary objectives were to evaluate the number of wounds requiring autografting and the number of dressing changes/local wound care required.

METHODS

Study wounds were identified on each patient and the patients were randomized to receive TransCyte or Biobrane or Silvazine. Assessment of study wound closure began at 2 days after treatment and continued at least every other day thereafter until the wounds re-epithelialized or were autografted. A laser Doppler imaging system was used as an adjunct to assessing the depth of the burn.

RESULTS

Thirty-three patients with 58 wound sites enrolled in the study (TransCyte, n = 20, Biobrane, n = 17; Silvazine, n = 21). Mean time to re-epithelialization was 7.5 days for TransCyte, 9.5 days for Biobrane, and 11.2 days for Silvazine. The number of wounds requiring autografting were 5/21 (24%) for Silvazine, 3/17 (17%) for Biobrane, and 1/20 (5%) for TransCyte.

CONCLUSIONS

When used in partial-thickness burns in children, TransCyte promotes fastest re-epithelialization and required less overall dressings then Biobrane or Silvazine. Patients who received Silvazine or Biobrane require more autografting than those treated with TransCyte.

摘要

背景

本研究的目的是比较三种烧伤敷料(TransCyte,一种生物工程皮肤替代物;Biobrane;以及Silvazine乳膏(磺胺嘧啶银和0.2%洗必泰))治疗儿童浅度烧伤的效果。主要目标是确定达到≥90%再上皮化所需的天数。次要目标是评估需要自体移植的伤口数量以及所需的换药次数/局部伤口护理次数。

方法

在每位患者身上确定研究伤口,患者被随机分配接受TransCyte、Biobrane或Silvazine治疗。治疗后第2天开始评估研究伤口的闭合情况,此后至少每隔一天评估一次,直至伤口再上皮化或进行自体移植。使用激光多普勒成像系统辅助评估烧伤深度。

结果

33例患者共58个伤口部位纳入研究(TransCyte组20例,Biobrane组17例,Silvazine组21例)。TransCyte组再上皮化的平均时间为7.5天,Biobrane组为9.5天,Silvazine组为11.2天。需要自体移植的伤口数量,Silvazine组为5/21(24%),Biobrane组为3/17(17%),TransCyte组为1/20(5%)。

结论

用于儿童浅度烧伤时,TransCyte促进再上皮化的速度最快,且总体所需敷料比Biobrane或Silvazine少。接受Silvazine或Biobrane治疗的患者比接受TransCyte治疗的患者需要更多的自体移植。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验